Announcement • Aug 15
Vyome Therapeutics Inc. completed the acquisition of ReShape Lifesciences Inc. (NasdaqCM:RSLS) in a reverse merger transaction. Vyome Therapeutics Inc. entered into a letter of intent to acquire ReShape Lifesciences Inc. (NasdaqCM:RSLS) in a reverse merger transaction on March 20, 2024. Vyome Therapeutics Inc. entered into a definitive merger agreement to acquire ReShape Lifesciences Inc in a reverse merger transaction on July 8, 2024. In a related transaction, ReShape entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd. to sell substantially all of its assets to Biorad. Under the terms of the merger agreement, existing ReShape stockholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape’s actual net cash at closing compared to a target net cash amount of $5 million. Vyome will own 88.9% of the combined company upon close of the transaction. At the closing of the merger, ReShape will be renamed Vyome Holdings, Inc. and expects to trade under the Nasdaq ticker symbol "HIND," representing the company’s alignment with the U.S.-India relationship. Vyome will be obligated to pay ReShape a $1 million termination fee in case of termination of the transaction under certain circumstances. ReShape will be obligated to pay Vyome a $1 million termination fee in case of termination of the transaction under certain circumstances. The board of directors of the combined company will be comprised of six directors designated by Vyome and one director designated by ReShape and executive management of the combined company will consist of Vyome’s executive officers.
The transaction is subject to certain closing conditions, including, among other things, approval by the stockholders of ReShape and Vyome, the Securities and Exchange Commission declaring effective ReShape’s registration statement registering the shares to be issued in connection to the merger, Nasdaq’s approval of the ReShape Shares to be issued in the Merger being listed on Nasdaq, the Nasdaq Stock Market's approval of the continued listing of the combined company in connection with the completion of the merger, completion of the Asset Sale immediately prior to the completion of the merger and ReShape having net cash of at least $1,325,000 million at the closing of the merger. The transaction has been unanimously approved by the boards of directors of both companies. The Registration Statement declared effective by the Securities and Exchange Commission on February 14, 2025. The Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET on July 24, 2025. As of August 7, 2025, shareholders of ReShape Lifesciences have approved all of the proposals necessary to complete the transaction. The transaction is expected to be effective for the commencement of trading on Friday, August 15, 2025.
As of August 7, 2025, ReShape majority stockholders approved and adopted the proposed amendments.
Maxim Group LLC is serving as financial advisor and fairness opinion provider to ReShape and Brett R. Hanson and Emily Humbert of Fox Rothschild LLP is acting as its legal counsels. Chardan Capital Markets, LLC is serving as financial advisor to Vyome for the merger and Gregory Sichenzia, Marcelle Balcombe and Glenn Burlingame of Sichenzia Ross Ference Carmel LLP is acting as its legal counsels. Innisfree M&A Incorporated acted as information agent to ReShape. ReShape will pay Innisfree a fee of up to $30,000. Equiniti Trust Company, LLC acted as transfer agent for ReShape.
Vyome Therapeutics Inc. completed the acquisition of ReShape Lifesciences Inc. (NasdaqCM:RSLS) in a reverse merger transaction on August 14, 2025. The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol “HIND.” Announcement • Jun 07
ReShape Lifesciences Inc. has filed a Follow-on Equity Offering. ReShape Lifesciences Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock Announcement • Jun 01
Nasdaq Determines to Delist ReShape Lifesciences' Securities from Nasdaq Due to Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement On May 28, 2025, ReShape Lifesciences Inc. (the ‘Company’) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) notifying the Company that Nasdaq has determined to delist the Company’s securities from Nasdaq. On November 25, 2024, Nasdaq notified the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b). However, Nasdaq granted the Company’s request for an extension until May 27, 2025 to comply with this requirement. Nasdaq has determined that the Company did not meet the terms of the extension. As a result, unless the Company requests an appeal of this determination by June 4, 2025, trading of the Company’s common stock will be suspended at the opening of business on June 6, 2025, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company intends to appeal Nasdaq’s decision to a hearings panel pursuant to the procedures set forth in the Nasdaq rules, which would stay the suspension of the Company’s securities pending the hearing panel’s decision. The Company can provide no assurance that, following the hearing, the hearings panel will grant the Company’s request for continued listing or that the Company can maintain compliance with the other Nasdaq Listing Rules. 
